1. Home
  2. ADCT vs GCO Comparison

ADCT vs GCO Comparison

Compare ADCT & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • GCO
  • Stock Information
  • Founded
  • ADCT 2011
  • GCO 1924
  • Country
  • ADCT Switzerland
  • GCO United States
  • Employees
  • ADCT N/A
  • GCO N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • GCO Clothing/Shoe/Accessory Stores
  • Sector
  • ADCT Health Care
  • GCO Consumer Discretionary
  • Exchange
  • ADCT Nasdaq
  • GCO Nasdaq
  • Market Cap
  • ADCT 241.0M
  • GCO 238.4M
  • IPO Year
  • ADCT 2020
  • GCO N/A
  • Fundamental
  • Price
  • ADCT $2.78
  • GCO $22.34
  • Analyst Decision
  • ADCT Strong Buy
  • GCO Hold
  • Analyst Count
  • ADCT 6
  • GCO 2
  • Target Price
  • ADCT $7.80
  • GCO $24.50
  • AVG Volume (30 Days)
  • ADCT 937.9K
  • GCO 359.0K
  • Earning Date
  • ADCT 08-05-2025
  • GCO 06-04-2025
  • Dividend Yield
  • ADCT N/A
  • GCO N/A
  • EPS Growth
  • ADCT N/A
  • GCO N/A
  • EPS
  • ADCT N/A
  • GCO N/A
  • Revenue
  • ADCT $75,817,000.00
  • GCO $2,341,438,000.00
  • Revenue This Year
  • ADCT $10.65
  • GCO $1.67
  • Revenue Next Year
  • ADCT $15.05
  • GCO $1.69
  • P/E Ratio
  • ADCT N/A
  • GCO N/A
  • Revenue Growth
  • ADCT 10.49
  • GCO 1.85
  • 52 Week Low
  • ADCT $1.05
  • GCO $16.19
  • 52 Week High
  • ADCT $4.13
  • GCO $44.80
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 47.62
  • GCO 52.78
  • Support Level
  • ADCT $3.21
  • GCO $21.24
  • Resistance Level
  • ADCT $3.97
  • GCO $22.64
  • Average True Range (ATR)
  • ADCT 0.38
  • GCO 1.39
  • MACD
  • ADCT -0.12
  • GCO -0.06
  • Stochastic Oscillator
  • ADCT 3.43
  • GCO 36.51

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About GCO Genesco Inc.

Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.

Share on Social Networks: